main pancreatic duct dilatation and/or the presence of pancreatic cysts
Conditions
Interventions
To perform a special ultrasound examination focusing on the pancreas (special pancreatic US) every 6 months and perform Magnetic Resonance Imaging (MRI) once a year.
Sponsors
Osaka International Cancer Institute
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The patients who satisfy one of the following conditions are included. 1. Patients who have dilatation of the MPD (2.5 mm and more) and a pancreatic cyst (5 mm and more). 2. Patients who have dilatation of the MPD (4 mm and more). 3. Patients who have a pancreatic cyst (20 mm and more). If the patients who have a family history of pancreatic cancer in first-degree relatives, it is allowed to participate in the study in the cases where MPD dilatation (2.5 mm and more) or a pancreatic cyst (5 mm and more) is detected.
Exclusion criteria
Exclusion criteria: 1. Pancreas is not clearly visualized by abdominal ultrasound. 2. Patients who have active or recent malignancies of other organs. 3. Severe comorbidities (such as renal failure, liver failure, heart failure). 4. Difficulty in MRI imaging. 5. Chronic pancreatitis is strongly suspected. 6. Patients who are diagnosed as high-risk stigmata according to the updated 2017 international guidelines on IPMN of the pancreas. 7. Patients who are diagnosed as other pancreatic cystic diseases (such as serious cystic neoplasm and mucinous cystic neoplasm). 8. Pregnant women or women of childbearing potential.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cumulative Incidence of neoplastic progression and the ratio of early detection in patients with neoplastic progression | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes of imaging findings and patient characteristics during surveillance, factors associated with early detection of neoplastic progression, The reasons and rates of detailed examinations such as ERCP and EUS-FNA, overall survival time in the patients with neoplastic progression, the rate of recurrence and recurrence-free survival time in the patients who undergo pancreatectomy. | — |
Countries
Japan
Contacts
Public ContactKazuyoshi Ohkawa
Osaka International Cancer Institute Department of Hepatobiliary and Pancreatic Oncology
Outcome results
None listed